The lancet oncology
The most recent articles from:
Lancet Oncol.
-
The lancet oncology · Jan 2017
Randomized Controlled Trial Multicenter StudyTumour-infiltrating lymphocytes in advanced HER2-positive breast cancer treated with pertuzumab or placebo in addition to trastuzumab and docetaxel: a retrospective analysis of the CLEOPATRA study.
High quantities of tumour-infiltrating lymphocytes (TILs) in primary HER2-positive breast cancer are associated with improved prognosis and response to therapy. We aimed to investigate the prognostic role of host antitumour immunity as represented by baseline quantities of TILs in patients with advanced HER2-positive breast cancer treated with either pertuzumab or placebo in addition to trastuzumab and docetaxel. ⋯ F Hoffmann-La Roche-Genentech and the Breast Cancer Research Foundation.